Monitor for partnership/licensing announcements for BMF-650 and upcoming icovamenib clinical milestones (COVALENT-211/212 Phase 2 data). The Phase 1 data is too early to change valuation materially; the key catalyst is whether a pharma partner validates the program with a licensing deal.
Price Chart
Executive Summary
Biomea Fusion announced Phase 1 data for oral GLP-1 RA BMF-650 showing 1.5%-3.2% weight reduction at Day 29 in outpatient cohorts vs 0.1% placebo, with mild GI tolerability and rapid one-step titration to 400 mg QD. The company plans to seek a strategic partnership for BMF-650 while focusing primary development on icovamenib for diabetes. The data is early (4-week, small sample) and the confined Cohort 5 results (6.1% weight loss) are confounded by placebo eating behavior, limiting read-through.
Key Facts
- Phase 1 GLP-131 trial: mean weight reduction 1.5%-3.2% at Day 29 across outpatient Cohorts 1-4 vs 0.1% pooled placebo
- No severe or serious TEAEs, no dose modifications or discontinuations across all BMF-650 MAD participants
- Cohort 5 (confinement, rapid one-step titration to 400 mg QD): mean weight reduction 6.1% (6.2 kg) at Day 29, but placebo participants consumed only ~33% of presented food, confounding results
- Nausea 17.5%, vomiting 7.5%, constipation 10%, diarrhea 5% across all active MAD cohorts; all GI events Grade 1
- Company plans to position BMF-650 for strategic partnership/licensing; primary focus remains on icovamenib in type 1 and type 2 diabetes
- Conference call scheduled for October 13, 2026 at 4:30 p.m. ET
Financial Impact
Early-stage Phase 1 data — no revenue or financial impact disclosed; partnership/licensing potential for BMF-650 is exploratory
Risk Factors
- Phase 1 data is only 4-week, small sample (n=40 active); longer-term durability and safety unknown
- Cohort 5 results confounded by placebo eating behavior under confinement — not directly comparable to outpatient cohorts
- Company is shifting BMF-650 to partnership model, implying limited internal late-stage resources; no partner secured yet
- Primary focus on icovamenib carries its own clinical and regulatory risks in diabetes
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3380154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6360 (−23.74%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6360 (−23.74%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6360 (−55.83%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6360 (+55.83%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6360 (+55.83%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6360 (−45.64%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6360 (−44.70%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6360 (−59.75%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6360 (−59.75%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6360 (−58.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers